Liquidia Technologies LQDA 深 沪
等待开盘 09-11 09:30:00 美东时间
27.29
-0.510
-1.83%
华盛通- 最 高27.9772
- 今 开27.645
- 成交量 226.26万股
- 最 低 27.26
- 昨 收 27.80
- 总市值 23.49亿
- 52周最高 29.94
- 市盈率 静 --
- 换手率 2.63%
- 52周最低 9.71
- 委 比 -79.99%
- 总股本 8609.15万
- 历史最高 38.46
- 量 比 1.12
- 振 幅 2.58%
- 历史最低 2.25
- 每 手 1
- 风险率 4.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is United Therapeutics Stock Rallying On Tuesday?
United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use.
09-02 22:59
Liquidia Analysts Raise Their Forecasts Following Q2 Results
Liquidia Corporation (NASDAQ:LQDA) reported a loss for the second quarter on Tu...
08-14 02:51
Why Is Liquidia Stock Trading Higher On Tuesday?
Liquidia Q2 sales hit $8.84 million after Yutrepia launch; PH-ILD study shows stable tolerability and improved walking distance at week 16.
08-13 02:25
Liquidia shares are trading higher. The company reported Q2 financial results.
Liquidia shares are trading higher. The company reported Q2 financial results.
08-12 20:55
In July And August Of 2025, Liquidia Analyzed Interim Data From The 52-week, Prospective, Open-label ASCENT Study Which Fully Enrolled 54 Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Safety data and observed exploratory efficacy data was summarized for Week 8 and Week 16 timepoints. The tolerability profile of YUTREPIA in PH-ILD was consistent with initial observations in the first 20 patients
08-12 18:36
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Liquidia Corporation announced strong performance for YUTREPIA™, achieving over 900 prescriptions and 550 treatments within 11 weeks post-approval. Positive interim data from the ASCENT trial highlighted its efficacy in PH-ILD. The company also revealed robust demand despite pending insurer approvals and presented financial results, which included decreased cash reserves and increased product revenue, alongside higher R&D and SG&A expenses. Their...
08-12 10:30
Liquidia Q2 2025 Earnings Preview
Liquidia (NASDAQ:LQDA) is scheduled to announce Q2 earnings results on Tuesday, August 12th, before market open. The consensus EPS Estimate is -$0.39 (-5.4% Y/Y) and the consensus Revenue Estimate is...
08-11 23:19
Earnings Preview For Liquidia
Liquidia (NASDAQ:LQDA) is gearing up to announce its quarterly earnings on Tues...
08-11 23:04
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025
Liquidia Corporation announced it will report its Q2 2025 financial results on August 12, 2025, followed by a webcast at 8:30 a.m. ET to discuss results and provide a corporate update. The webcast will be available on the company’s website, with a rebroadcast archived for one year. Liquidia, a biopharmaceutical company, focuses on developing innovative therapies for rare cardiopulmonary diseases, including pulmonary hypertension, using its propri...
08-05 12:30
